ABCL EPS
Net income divided by diluted shares outstanding — the per-share profit earned each quarter.
EPS
Latest: -$0.18 (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | -$0.14 |
| 2023Q2 | -$0.11 |
| 2023Q3 | -$0.10 |
| 2023Q4 | -$0.16 |
| 2024Q1 | -$0.14 |
| 2024Q2 | -$0.13 |
| 2024Q3 | -$0.17 |
| 2024Q4 | -$0.12 |
| 2025Q1 | -$0.15 |
| 2025Q2 | -$0.12 |
| 2025Q3 | -$0.19 |
| 2025Q4 | -$0.03 |
| 2026Q1 | -$0.14 |
| 2026Q2 | -$0.18 |
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 6
Revenue
Free Cash Flow
FCF Margin
Cumulative FCF
Shares Outstanding
Total Assets
Healthcare Comparison
1 / 3
Latest EPS: -$0.18 (2026Q2); -50.0% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, EPS ranged from -$0.19 in 2025Q3 to -$0.03 in 2025Q4.